Vice President
Novavax
Disclosure(s): Novavax, Inc.: employee, Stocks/Bonds (Public Company)
Dr. Vivek Shinde is Vice President, Clinical Development with responsibility of leading the clinical development programs for COVID-influenza combination and influenza vaccines. He is a research physician and biotech executive with specialty training in internal medicine, preventive medicine, global health, clinical research, and epidemiology from UCSF, Johns Hopkins, NYU, and the U.S. Centers for Disease Control. He has over a decade and a half of combined research and global health experience in influenza, RSV, and viral respiratory disease research, including vaccine clinical development (leading mid- and late-stage vaccine development programs), vaccine pharmacoepidemiology (leading large post-marketing safety and effectiveness trials), real world evidence research, and infectious disease epidemiology. Prior to joining Novavax in August 2015, he held various scientific and strategic leadership positions through key roles in public and private sector organizations at the local, national, and international levels, including the U.S.-CDC, the NYC DoH, WHO-HQ Geneva and GlaxoSmithKline Vaccines.